ISPC Quote, Financials, Valuation and Earnings

Delcath Systems, Inc. has a net margin of -2608.44% compared to iSpecimen, Inc.'s net margin of 4.04%. iSpecimen, Inc.'s return on equity of -430.7% beat Delcath Systems, Inc.'s return on equity of 1.59%.

iSpecimen, Inc. has a consensus price target of --, signalling upside risk potential of 15606.81%. On the other hand Delcath Systems, Inc. has an analysts' consensus of $22.31 which suggests that it could grow by 116.55%. Given that iSpecimen, Inc. has higher upside potential than Delcath Systems, Inc., analysts believe iSpecimen, Inc. is more attractive than Delcath Systems, Inc..

iSpecimen, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Delcath Systems, Inc. has a beta of 0.410, suggesting its less volatile than the S&P 500 by 59.033%.

iSpecimen, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Delcath Systems, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. iSpecimen, Inc. pays -- of its earnings as a dividend. Delcath Systems, Inc. pays out -- of its earnings as a dividend.

iSpecimen, Inc. quarterly revenues are $106.6K, which are smaller than Delcath Systems, Inc. quarterly revenues of $20.6M. iSpecimen, Inc.'s net income of -$2.8M is lower than Delcath Systems, Inc.'s net income of $830K. Notably, iSpecimen, Inc.'s price-to-earnings ratio is -- while Delcath Systems, Inc.'s PE ratio is 1,183.91x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for iSpecimen, Inc. is 0.33x versus 4.91x for Delcath Systems, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

RadNet, Inc. has a net margin of -2608.44% compared to iSpecimen, Inc.'s net margin of 2.66%. iSpecimen, Inc.'s return on equity of -430.7% beat RadNet, Inc.'s return on equity of 1.82%.

iSpecimen, Inc. has a consensus price target of --, signalling upside risk potential of 15606.81%. On the other hand RadNet, Inc. has an analysts' consensus of $91.71 which suggests that it could grow by 25.38%. Given that iSpecimen, Inc. has higher upside potential than RadNet, Inc., analysts believe iSpecimen, Inc. is more attractive than RadNet, Inc..

iSpecimen, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison RadNet, Inc. has a beta of 1.485, suggesting its more volatile than the S&P 500 by 48.541%.

iSpecimen, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. RadNet, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. iSpecimen, Inc. pays -- of its earnings as a dividend. RadNet, Inc. pays out -- of its earnings as a dividend.

iSpecimen, Inc. quarterly revenues are $106.6K, which are smaller than RadNet, Inc. quarterly revenues of $522.9M. iSpecimen, Inc.'s net income of -$2.8M is lower than RadNet, Inc.'s net income of $13.9M. Notably, iSpecimen, Inc.'s price-to-earnings ratio is -- while RadNet, Inc.'s PE ratio is 1,513.25x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for iSpecimen, Inc. is 0.33x versus 2.81x for RadNet, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Star Operating Cos., Inc. has a net margin of -2608.44% compared to iSpecimen, Inc.'s net margin of 14.56%. iSpecimen, Inc.'s return on equity of -430.7% beat Star Operating Cos., Inc.'s return on equity of -3.67%.

iSpecimen, Inc. has a consensus price target of --, signalling upside risk potential of 15606.81%. On the other hand Star Operating Cos., Inc. has an analysts' consensus of $12.00 which suggests that it could grow by 9.89%. Given that iSpecimen, Inc. has higher upside potential than Star Operating Cos., Inc., analysts believe iSpecimen, Inc. is more attractive than Star Operating Cos., Inc..

iSpecimen, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Star Operating Cos., Inc. has a beta of 2.714, suggesting its more volatile than the S&P 500 by 171.399%.

iSpecimen, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Star Operating Cos., Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. iSpecimen, Inc. pays -- of its earnings as a dividend. Star Operating Cos., Inc. pays out 19.54% of its earnings as a dividend. Star Operating Cos., Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

iSpecimen, Inc. quarterly revenues are $106.6K, which are smaller than Star Operating Cos., Inc. quarterly revenues of $23.7M. iSpecimen, Inc.'s net income of -$2.8M is lower than Star Operating Cos., Inc.'s net income of $3.5M. Notably, iSpecimen, Inc.'s price-to-earnings ratio is -- while Star Operating Cos., Inc.'s PE ratio is 0.75x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for iSpecimen, Inc. is 0.33x versus 0.52x for Star Operating Cos., Inc.. Usually stocks with elevated PS ratios are considered overvalued.